Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

Hovater, Michael B.; Jaimes, Edgar A.

doi:10.2147/ibpc.s32649

Cited by 3 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug combinations with AD include aliskiren and hydrochlorothiazide [98, 99], olmesartan and hydrochlorothiazide [67, 100–102], and valsartan and hydrochlorothiazide [88, 95, 101–103]. …”

Section: Formulations Of Admentioning

confidence: 99%

Formulations of Amlodipine: A Review

Sheraz

Ahsan

Khan

et al. 2016

Journal of Pharmaceutics

View full text Add to dashboard Cite

Amlodipine (AD) is a calcium channel blocker that is mainly used in the treatment of hypertension and angina. However, latest findings have revealed that its efficacy is not only limited to the treatment of cardiovascular diseases as it has shown to possess antioxidant activity and plays an important role in apoptosis. Therefore, it is also employed in the treatment of cerebrovascular stroke, neurodegenerative diseases, leukemia, breast cancer, and so forth either alone or in combination with other drugs. AD is a photosensitive drug and requires protection from light. A number of workers have tried to formulate various conventional and nonconventional dosage forms of AD. This review highlights all the formulations that have been developed to achieve maximum stability with the desired therapeutic action for the delivery of AD such as fast dissolving tablets, floating tablets, layered tablets, single-pill combinations, capsules, oral and transdermal films, suspensions, emulsions, mucoadhesive microspheres, gels, transdermal patches, and liposomal formulations.

show abstract

Section: Formulations Of Admentioning

confidence: 99%

Formulations of Amlodipine: A Review

Sheraz

Ahsan

Khan

et al. 2016

Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…It includes mono and combination therapy with βblockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotension II receptor blockers (ARB) and calcium channel antagonists. 3,4 Aliskiren chemically, (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamidehemifumarate. 5 It is a non-peptide, first orally taken direct renin inhibitor simulating endogenous peptides approved for clinical use in the treatment of hypertension from the United States Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

Ich Guideline Practice: A Validated Stability Indicating Rp-Uplc Method Development and Its Application for Determination of Aliskiren and Amlodipine in Bulk and Formulation

Vasavidevi¹,

Swarnalatha²,

Subbareddy³

2018

RJC

View full text Add to dashboard Cite

A novel, accurate, specific and robust reverse phase liquid chromatographic method was developed and validated for the simultaneous estimation of Aliskiren and Amlodipine besylate in bulk and tablet dosage form. A reverse phase stability indicating Ultra High-Performance Liquid Chromatography (UHPLC) method was developed on an SD 3*100 mm x 1.8 µ column using isocratic elution of acetonitrile and 0.1% perchloric acid buffer (pH 2.6-2.8) in the ratio 60: 40 at a flow rate of 0.5 ml/min. The detection was carried out by using Acquity TUV ChA at 266nm. The total run time was 2.5 min and the retention time of amlodipine and Aliskiren were found to be 1.006 and 1.329 min respectively. According to ICH guidelines, forced degradation conditions were employed to establish the stability indicating method. The LOD and LOQ of Aliskiren and Amlodipine were found to be 0.17 µg/ml, 0.51 µg/ml and 0.03 µg/ml, 0.10 µg/ml respectively. The developed method was validated as per ICH guidelines for linearity, accuracy, precision, robustness and stability indicating studies and the method was successfully applied for the estimation of aliskiren and amlodipine in combined tablet dosage form.

show abstract